Impact of experimental hypercalcemia on routine haemostasis testing.

BACKGROUND:The blood to anticoagulant ratio is standardized according to the physiological calcium concentration in blood samples conventionally used for hemostasis testing. Specifically, one fixed volume of 0.109 mmol/L sodium citrate is added to 9 volumes of blood. Since little is known about the...

Full description

Bibliographic Details
Main Authors: Giuseppe Lippi, Gian Luca Salvagno, Giorgio Brocco, Matteo Gelati, Elisa Danese, Emmanuel J Favaloro
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5376338?pdf=render
id doaj-8148cbaef7ad4c7baf2e1cfe91cb7f1e
record_format Article
spelling doaj-8148cbaef7ad4c7baf2e1cfe91cb7f1e2020-11-25T01:22:53ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01123e017509410.1371/journal.pone.0175094Impact of experimental hypercalcemia on routine haemostasis testing.Giuseppe LippiGian Luca SalvagnoGiorgio BroccoMatteo GelatiElisa DaneseEmmanuel J FavaloroBACKGROUND:The blood to anticoagulant ratio is standardized according to the physiological calcium concentration in blood samples conventionally used for hemostasis testing. Specifically, one fixed volume of 0.109 mmol/L sodium citrate is added to 9 volumes of blood. Since little is known about the impact of hypercalcemia on the calcium-binding capacity of citrate, this study was planned to investigate the effect of experimental hypercalcemia on routine hemostasis testing. METHODS:Fifteen pooled citrated plasmas with matching lithium-heparin pooled plasma from patients with different values of prothrombin time (PT) were divided in three aliquots of 0.6mL each. The first paired aliquots of both citrate and lithium-heparin plasma were supplemented with 60μL of saline, the second paired aliquots with 30μL of saline and 30μL of calcium chloride and the third paired aliquots with 60μL of calcium chloride. Total and ionized calcium was measured in all aliquots of citrate and lithium-heparin plasma, whereas PT, activated partial thromboplastin time (APTT) and fibrinogen were measured in citrate plasma aliquots. RESULTS:Total calcium concentration gradually increased in both lithium-heparin and citrate plasma aliquots 2 and 3 compared to baseline aliquot 1. The concentration of ionized calcium also gradually increased in lithium-heparin plasma aliquots 2 and 3, whereas it remained immeasurable (i.e., <0.10 mmol/L) in all citrate plasma aliquots. No significant differences were observed for values of PT, APTT and fibrinogen in citrate plasma aliquots 2 and 3 compared to the baseline aliquot 1, with a mean bias was always comprised within the desirable quality specifications derived from biological variability data. CONCLUSION:Hypercalcemia, up to severe hypercalcemia does not generate significant bias in results of first-line coagulations tests, so that hypothetical consideration of adjusting citrate-blood ratio is unjustified in hypercalcemic patients.http://europepmc.org/articles/PMC5376338?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Giuseppe Lippi
Gian Luca Salvagno
Giorgio Brocco
Matteo Gelati
Elisa Danese
Emmanuel J Favaloro
spellingShingle Giuseppe Lippi
Gian Luca Salvagno
Giorgio Brocco
Matteo Gelati
Elisa Danese
Emmanuel J Favaloro
Impact of experimental hypercalcemia on routine haemostasis testing.
PLoS ONE
author_facet Giuseppe Lippi
Gian Luca Salvagno
Giorgio Brocco
Matteo Gelati
Elisa Danese
Emmanuel J Favaloro
author_sort Giuseppe Lippi
title Impact of experimental hypercalcemia on routine haemostasis testing.
title_short Impact of experimental hypercalcemia on routine haemostasis testing.
title_full Impact of experimental hypercalcemia on routine haemostasis testing.
title_fullStr Impact of experimental hypercalcemia on routine haemostasis testing.
title_full_unstemmed Impact of experimental hypercalcemia on routine haemostasis testing.
title_sort impact of experimental hypercalcemia on routine haemostasis testing.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description BACKGROUND:The blood to anticoagulant ratio is standardized according to the physiological calcium concentration in blood samples conventionally used for hemostasis testing. Specifically, one fixed volume of 0.109 mmol/L sodium citrate is added to 9 volumes of blood. Since little is known about the impact of hypercalcemia on the calcium-binding capacity of citrate, this study was planned to investigate the effect of experimental hypercalcemia on routine hemostasis testing. METHODS:Fifteen pooled citrated plasmas with matching lithium-heparin pooled plasma from patients with different values of prothrombin time (PT) were divided in three aliquots of 0.6mL each. The first paired aliquots of both citrate and lithium-heparin plasma were supplemented with 60μL of saline, the second paired aliquots with 30μL of saline and 30μL of calcium chloride and the third paired aliquots with 60μL of calcium chloride. Total and ionized calcium was measured in all aliquots of citrate and lithium-heparin plasma, whereas PT, activated partial thromboplastin time (APTT) and fibrinogen were measured in citrate plasma aliquots. RESULTS:Total calcium concentration gradually increased in both lithium-heparin and citrate plasma aliquots 2 and 3 compared to baseline aliquot 1. The concentration of ionized calcium also gradually increased in lithium-heparin plasma aliquots 2 and 3, whereas it remained immeasurable (i.e., <0.10 mmol/L) in all citrate plasma aliquots. No significant differences were observed for values of PT, APTT and fibrinogen in citrate plasma aliquots 2 and 3 compared to the baseline aliquot 1, with a mean bias was always comprised within the desirable quality specifications derived from biological variability data. CONCLUSION:Hypercalcemia, up to severe hypercalcemia does not generate significant bias in results of first-line coagulations tests, so that hypothetical consideration of adjusting citrate-blood ratio is unjustified in hypercalcemic patients.
url http://europepmc.org/articles/PMC5376338?pdf=render
work_keys_str_mv AT giuseppelippi impactofexperimentalhypercalcemiaonroutinehaemostasistesting
AT gianlucasalvagno impactofexperimentalhypercalcemiaonroutinehaemostasistesting
AT giorgiobrocco impactofexperimentalhypercalcemiaonroutinehaemostasistesting
AT matteogelati impactofexperimentalhypercalcemiaonroutinehaemostasistesting
AT elisadanese impactofexperimentalhypercalcemiaonroutinehaemostasistesting
AT emmanueljfavaloro impactofexperimentalhypercalcemiaonroutinehaemostasistesting
_version_ 1725124887276683264